March 2014

Contents

Editorial

• March/April 2014: Volume 15 Number 3/4

Conference reports

• 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

• No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

• PrEP injections every three months may protect against exposure from anal sex

• ARV pipeline: doravirine, GSK-744 and BMS-068

• Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

• Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

• Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

• Pharmacokinetic targets for efavirenz might be too high

• Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

• NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

• HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

• Lower newborn bone mineral content with maternal tenofovir use

• Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

• Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

• Xpert TB test has important advantages but does not reduce morbidity

• Reports of a second baby possibly cured of HIV: uncertainty remains

• Updates on SB728-T, a CCR5-targeting gene therapy

Treatment access

• FDA approvals of generic ARVS

Paediatric care

• FDA approves raltegravir for children older than 4 weeks

Guidelines

• UK guidelines for HIV-related cancers (2014): published online

• Draft BHIVA pregnancy guidelines (2014) online for comment

• Strong recommendations in WHO 2014 guidelines are often based on lower quality evidence than indicated in GRADE approach

Hepatitis coinfection

• Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

• New treatments for HCV: strategies for achieving universal access

Basic science and immunology

• The prognostic value of interleukin-6 and D-dimer levels in primary HIV infection

• HIV reservoir: CD4 T stem cells may facilitate long-term persistence

• Update published on the first Berlin patient

• Poor CD4 T cell recovery despite HIV suppression linked to increased morbidity and mortality

• The relevance of the CD4/CD8 ratio in the ART era

• First human trial of AAV as a delivery vehicle for HIV neutralising antibodies gets underway

On the web

• Conference resources

• Online articles

PDFs

• Volume 15 Number 3/4 March/April 2014 PDF